Lechner 2019.

Study characteristics
Methods	Study design: secondary analysis of RCT Country: USA Data collection period: not stated Registry ID: not reported
Participants	Number of participants: N = 150; Number included in meta‐analysis: N = 37 Sample characteristics (at baseline): Age (mean): 42.1 years (SD 12.7); Sex (% male): 58.7% (88/150) Population category: general population; Specific population: people who were drinking heavily and smoking (at least once per month on average (≥ 4 drinks per occasion for women; ≥ 5 drinks for men)) recruited from the community Nicotine dependence: FTCD 5.3 (SD 2.3); Baseline cigarettes per day: 17.9 (SD 9.5); Motivation to quit: selected by motivation to quit
Interventions	Behavioural support for smoking cessation: participants received 6‐sessions of counselling that addressed heavy drinking and smoking. The Counseling and Medication Management (CMM) intervention provided (i) smoking cessation treatment consistent with clinical practice guidelines, (ii) counselling on alcohol and its impact on smoking cessation, and (iii) monitoring of oral study medication use and safety following guidelines in medical management – in addition to standard smoking cessation modules, session 1 included normative feedback on drinking and discussion of goals related to short‐ and long‐term changes in drinking. subsequent sessions focused on study medication use, side effects, progress in quitting smoking, provision of support, review of current drinking, efforts to modify drinking, and problem‐solving for high‐risk situations for smoking relapse; a quit date was set in the second week of the 10‐week treatment Pharmacological support for smoking cessation: participants received 6 weeks of transdermal nicotine patches; participants were drawn from a parent study in which they were randomised to receive 10 weeks of either i) 50 mg naltrexone (n = 75), or ii) placebo (n = 75) daily Psychotherapeutic or psychoactive support for mental health or mood: did not receive mood management
Outcomes	Definition of cessation used: 7‐day point‐prevalence smoking abstinence was assessed at 2, 8, 16, and 26 weeks after quit date and was bioverified Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: expired CO ( ≤ 4 ppm) Definition of people who continued to smoke used: exact definition not reported; ‘no significant change in use relevant to baseline’ Time point(s) at which follow‐up was conducted: 2, 8, 16, and 26 weeks after quit date Outcome category: Depression Outcome measure(s): Center for Epidemiologic Studies Depression Scale (CES‐D)
Funding source	This study was supported by NIHNIAAA R01‐ AA01718 (Kahler)
Author conflicts of interest	No conflict declared
Notes	Outcome data source: Published data